CR Bard acquires MedChem Products in stock-swap deal
This article was originally published in Clinica
CR Bard will take over MedChem Products in a stock-for-stock deal worth $100 million. Under an agreement signed on May 24th, Bard will pay $9.25 for each of the 11 million outstanding MedChem shares. This represents a 42% premium on the pre-bid price of MedChem stock which closed at $6.50 on May 23rd.